Severity of COVID-19	Mean	SD	Min	Max	CI 95%		Median	IQR	PN	PKV	Statistical analysis PKV PT or MV
A– (placebo)
Mild	-6.46	54.31	-71.8	112.4	-51.86	38.94	-8.5	42.38	>0.05	0.96	0.92
Medium	-11.84	55.8	-121.8	141.5	-37.24	13.56	-4.2	40.05	<0.05
Severe	-14.88	57.83	-95	61.3	-86.68	56.92	-6	101.2	>0.05
B+ (Vitamin D)
Mild	-19.33	30.88	-88	8.4	-45.14	6.49	-10	32.45	<0.05	0.82	Mo: 0.35,Mi: 0.92, S: 0.79
Medium	-13.39	37.4	-60.3	105.6	-30.9	4.12	-18.05	38.78	<0.05
Severe	-20.91	41.1	-87.8	70.1	-42.04	0.22	-21	63.35	>0.05

Table 1 : True case and true placebo groups.

Group	Indicator					Statistical analysis
Group	Mean	SD	Min	Max	CI 95%	Median	Median	IQR	PN	PT or MV	η
	Age years
A (placebo)	67.08	13.53	34.00	88.00	63.15	71.01	68.00	20.50	>0.05	0.15	0.15
B (Vitamin D)	63.10	13.88	34.00	90.00	59.23	66.96	61.00	19.50	>0.05
BMI, kg/m2
A (placebo)	28.85	5.86	19.59	47.75	27.14	30.55	27.09	7.69	<0.05	0.38	0.10
B (Vitamin D)	30.17	7.26	20.96	62.28	28.15	32.19	28.66	9.48	>0.05
GFR, ml/min/1.73m2
A (placebo)	78.33	28.44	36.00	138.50	70.07	86.59	72.60	41.70	>0.05	0.60	0.06
B (Vitamin D)	81.77	30.21	34.30	165.50	73.36	90.19	78.55	38.33	>0.05
25(OH)D levels, ng/ml (norm: >30 ng/ml)
A (placebo)	17.11	7.04	6.44	27.83	15.07	19.16	15.54	14.22	<0.05	0.23	0.12
B (Vitamin D)	15.54	6.34	7.02	26.62	13.77	17.30	13.29	12.15	<0.05
C-reactive protein, mg/l (norm: < 8 mg/l)
A (placebo)	66.30	43.82	3.99	174.26	53.57	79.02	59.83	69.69	>0.05	0.12	0.24
B (Vitamin D)	96.80	76.88	3.99	279.52	75.40	118.20	72.94	106.15	<0.05
Ferritin, ng/ml (norm: 12 – 122 ng/ml or 20 – 250 ng/ml)
A (placebo)	623.60	461.54	47.701 741.00		489.59	757.62	505.10	630.93	<0.05	0.66	0.03
B (Vitamin D)	647.92	461.04	17.701 808.00		519.57	776.28	570.50	568.40	>0.05

SD – standard deviation; IQR - interquartile range; CI 95% - confidential interval of 95%; PN - statistically significant of normality of data in group; PPT or V - statistical reliability for paired data with paired T test or Wilcoxon signed-rank test; PMV – statistical reliability of the difference in delta medians between the two groups (A vs B) using the Mann-Whitney U test.
Table sp 2 : Changes in 25(OH)D levels, ng/ml, before and after (Day 1 and Day 6) in groups A and B with all patients (ITT analysis)

Group	Total amount of patients	Response to vitamin D therapy
		CvitD2> CvitD1+CV		CvitD2< CvitD1+CV
		Amount	%	Amount	%
A ( placebo)	48	14	29.2	34	70.7
B (vitamin D)	51	46	90.2	5	9.8

Disease severity	Group				Statistical analysis
	A- (placebo)		B+ (Vitamin D)		P χ	V
	Amount	%	Amount	%	P χ	V
Mild	8	23.53	8	17.39	0.06	0.27
Medium	21	61.76	20	43.48
Severe	5	14.71	18	39.13
Total	34	100%	46	100%

Group	Delta values				Statistical analysis
Group	Mean, ng/ml	SD, ng/ml	Median, ng/ml	IQR	P MV	η
A- (placebo)	-1.87	1.97	-1.88	3.05	-14 2.72 x10	0.44
B+ (vitamin D)	8.69	7.63	5.82	8.37	-14 2.72 x10	0.44

Severity of COVID-19	Delta values (25(OH)D)				Statistical analysis
Severity of COVID-19	Mean, ng/ml	SD, ng/ml	Median, ng/ml	IQR	P * F or KV	P P ^ KV T or MV
A- (placebo)						-11 -4 1.44 x10 Mi: 3,10 x10 Mo: -8 -4 4.31 x10 S: 7.96 x10
Mild	-1.58	2.15	-2.14	3.97	0,43
Moderate	-1.72	1.83	-1.83	3.03
Severe	-2.93	2.31	-4.08	4.35
B+ (vitamin D)
Mild	5.53	3.65	4.06	5.86	0.14
Moderate	6.57	3.64	5.46	4.14
Severe	12.44	10.43	7.92	14.51

Group	Delta values				Statistical analysis
Group	Mean, ng/ml	SD, ng/ml	Median, ng/ml	IQR	P MV	η
A- (placebo)	-18.77	54.17	-15.59	46.85	-2 4,24 x10	0.05
B+ (vitamin D)	-52.98	82.34	-37.74	87.57	-2 4,24 x10	0.05

Tables at a glance

Figures at a glance

Severity of COVID-19	Delta values (CRP)				Statistical analysis
Severity of COVID-19	Mean, ng/ml	SD, ng/ml	Median, ng/ml	IQR	P F	P P ^ F T
A- (placebo)						0.31 Mi: 0.69Mo: 4.06 -2 x10 S: 0.82
Mild	-23.69	36.09	-20.77	51.40	0.57
Moderate	-11.81	54.23	-11.02	44.97
Severe	-40.15	79.70	-19.00	147.03
B+ (vitamin D)
Mild	-32.05	42.62	-20.73	73.75	0.50
Moderate	-64.60	96.72	-64.40	145.62
Severe	-49.38	79.79	-40.27	66.68

Group	Delta values				Statistical analysis
Group	Mean, pg/ml	SD , pg/ml	Median, pg/ml	IQR	P MV	η
A- (placebo)	-10.99	54.93	-4.20	43.95	0.29	0.01
B+ (vitamin D)	-17.29	37.18	-20.90	41.60	0.29	0.01

Measur	25(OH)D, ng/ml, levels						Statistical analysis
ement	Mean	SD	Min	Max	CI 95%		Median	IQR	PN	PPT or V*	PMV
					A (placebo)
Day 1	17,11	7,04	6,44	27,83	15,0719,16		15,54	14,22	<0,05
Day 6	16,87	8,45	6,40	39,34	14,4119,32		13,86	14,43	>0,05	0,63 / 0,26
Delta	-0,25	3,49	-5,33	12,61	-1,260,77B (Vitamin D)		-0,46	4,81	>0,05	-	-6 1,63 x10
Day 1	15,54	6,34	7,02	26,62	13,77	17,30	13,29	12,15	<0,05
Day 6	23,30	9,99	10,06	58,34	20,52	26,08	22,81	13,44	<0,05	-10 6,64 x10
Delta	-54,42	84,50	-274,84	130,65	-77,95	-30,90	-35,88	86,60	<0,05

Measurement	CRP, ng/ml, levels									Statistical analysis

	Mean	SD	Min	Max	CI 95%		Median	IQR	PN	PPT or V	PMV
A (placebo)
Day 1	66,30	43,82	3,99	174,26	53,5779,02		59,83	69,69	<0,05
Day 6	39,54	39,05	3,99	160,62	28,2050,88		27,34	44,14	<0,05	-4 5,39 x10
Delta	-26,76	53,57	-169,18	113,33	-42,31-11,21		-18,62	59,69	>0,05	-	0,10
B (Vitamin D)
Day 1	96,80	76,88	3,99	279,52	75,40	118,20	72,94	106,15	<0,05
Day 6	42,38	52,31	3,99	224,96	27,82	56,94	19,59	49,58	<0,05	-5 2,38 x10
Delta	-54,42	84,50	274,84	-130,65	-77,95	-30,90	-35,88	86,60	<0,05